Journal
SEMINARS IN IMMUNOLOGY
Volume 21, Issue 5, Pages 293-300Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2009.05.012
Keywords
CD40; CD154; Autoimmune disease; Polymorphism; T lymphocyte; B lymphocyte
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA099997] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049993] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA099997-06A2, R01 CA099997] Funding Source: Medline
- NIAID NIH HHS [R01 AI049993, R01 AI049993-03] Funding Source: Medline
- NIGMS NIH HHS [T32 GM007337] Funding Source: Medline
Ask authors/readers for more resources
CD40 is a tumor necrosis factor receptor superfamily member expressed by immune and non-immune cells. CD40:CD154 interactions mediate T-dependent B cell responses and efficient T cell priming. Thus, CD40 is a likely candidate to play roles in autoimmune diseases in which activated T and B cells cause pathology. Diseases in which CD40 plays a pathogenic role include autoimmune thyroiditis, type 1 diabetes, inflammatory bowel disease, psoriasis, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. This review discusses the role of CD40:CD154 interaction in human and mouse autoimmunity, human polymorphisms associated with disease incidence, and disrupting CD40: CD154 interactions as an autoimmune therapy. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
